Tags

Type your tag names separated by a space and hit enter

Tocilizumab and COVID-19: a meta-analysis of 2120 patients with severe disease and implications for clinical trial methodologies
Turk J Med Sci. 2021 06 28; 51(3):890-897.TJ

Abstract

Background/aim

Since the outbreak of the COVID-19, numerous therapies to counteract this severe disease have emerged. The benefits of Tocilizumab for severely infected COVID-19 patients and the methodologies of ongoing clinical trials are explored.

Materials and methods

A systematic search adhering to PRISMA guidelines was conducted in PubMed, Cochrane Central, medRxiv, and bioRxiv using the following keywords: “Tocilizumab,” “Actemra,” “COVID-19.” An additional subsearch was conducted on Clinicaltrials.gov to locate ongoing tocilizumab trials.

Results

A total of 13 studies were included in the meta-analysis comprising 2120 patients. The treatment group had lower mortality compared to the control group (OR = 0.42, 95% CI = 0.26 to 0.69, P = 0.0005, I2 = 55%). A descriptive analysis of 50 registered trials was conducted.

Conclusion

This review meta-analyzed the therapeutic benefits of tocilizumab in COVID-19 patients with severe disease for mortality, mechanical ventilation, and the characteristics of COVID-19 registered trials.

Authors+Show Affiliations

Department of Pediatrics and Child Health, Aga Khan University, Karachi, PakistanResearch Department, Fatima Jinnah Medical University, Lahore, PakistanDepartment of Physiology, CMH Lahore Medical and Dental College, Lahore, PakistanResearch Department CMH Lahore Medical and Dental College, Lahore, PakistanResearch Department CMH Lahore Medical and Dental College, Lahore, Pakistan

Pub Type(s)

Journal Article
Meta-Analysis
Systematic Review

Language

eng

PubMed ID

33244947

Citation

Sarfraz, Azza, et al. "Tocilizumab and COVID-19: a Meta-analysis of 2120 Patients With Severe Disease and Implications for Clinical Trial Methodologies." Turkish Journal of Medical Sciences, vol. 51, no. 3, 2021, pp. 890-897.
Sarfraz A, Sarfraz Z, Sarfraz M, et al. Tocilizumab and COVID-19: a meta-analysis of 2120 patients with severe disease and implications for clinical trial methodologies. Turk J Med Sci. 2021;51(3):890-897.
Sarfraz, A., Sarfraz, Z., Sarfraz, M., Aftab, H., & Pervaiz, Z. (2021). Tocilizumab and COVID-19: a meta-analysis of 2120 patients with severe disease and implications for clinical trial methodologies. Turkish Journal of Medical Sciences, 51(3), 890-897. https://doi.org/10.3906/sag-2010-131
Sarfraz A, et al. Tocilizumab and COVID-19: a Meta-analysis of 2120 Patients With Severe Disease and Implications for Clinical Trial Methodologies. Turk J Med Sci. 2021 06 28;51(3):890-897. PubMed PMID: 33244947.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tocilizumab and COVID-19: a meta-analysis of 2120 patients with severe disease and implications for clinical trial methodologies AU - Sarfraz,Azza, AU - Sarfraz,Zouina, AU - Sarfraz,Muzna, AU - Aftab,Hinna, AU - Pervaiz,Zainab, Y1 - 2021/06/28/ PY - 2020/10/13/received PY - 2020/11/26/accepted PY - 2020/11/27/entrez PY - 2020/11/28/pubmed PY - 2021/7/6/medline KW - Tocilizumab KW - actemra KW - coronavirus KW - COVID-19 KW - clinical trial KW - cytokine storm syndrome SP - 890 EP - 897 JF - Turkish journal of medical sciences JO - Turk J Med Sci VL - 51 IS - 3 N2 - Background/aim: Since the outbreak of the COVID-19, numerous therapies to counteract this severe disease have emerged. The benefits of Tocilizumab for severely infected COVID-19 patients and the methodologies of ongoing clinical trials are explored. Materials and methods: A systematic search adhering to PRISMA guidelines was conducted in PubMed, Cochrane Central, medRxiv, and bioRxiv using the following keywords: “Tocilizumab,” “Actemra,” “COVID-19.” An additional subsearch was conducted on Clinicaltrials.gov to locate ongoing tocilizumab trials. Results: A total of 13 studies were included in the meta-analysis comprising 2120 patients. The treatment group had lower mortality compared to the control group (OR = 0.42, 95% CI = 0.26 to 0.69, P = 0.0005, I2 = 55%). A descriptive analysis of 50 registered trials was conducted. Conclusion: This review meta-analyzed the therapeutic benefits of tocilizumab in COVID-19 patients with severe disease for mortality, mechanical ventilation, and the characteristics of COVID-19 registered trials. SN - 1303-6165 UR - https://www.unboundmedicine.com/medline/citation/33244947/Tocilizumab_and_COVID_19:_a_meta_analysis_of_2120_patients_with_severe_disease_and_implications_for_clinical_trial_methodologies L2 - https://doi.org/10.3906/sag-2010-131 DB - PRIME DP - Unbound Medicine ER -